Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 0.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,953 shares of the medical research company’s stock after acquiring an additional 33 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Charles River Laboratories International were worth $703,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of CRL. Canada Pension Plan Investment Board lifted its position in Charles River Laboratories International by 75.3% during the 1st quarter. Canada Pension Plan Investment Board now owns 12,800 shares of the medical research company’s stock worth $1,151,000 after acquiring an additional 5,500 shares during the period. Great West Life Assurance Co. Can lifted its position in Charles River Laboratories International by 6.9% during the 1st quarter. Great West Life Assurance Co. Can now owns 40,025 shares of the medical research company’s stock worth $3,600,000 after acquiring an additional 2,570 shares during the period. Suntrust Banks Inc. lifted its position in Charles River Laboratories International by 15.8% during the 1st quarter. Suntrust Banks Inc. now owns 6,624 shares of the medical research company’s stock worth $594,000 after acquiring an additional 904 shares during the period. Comerica Bank lifted its position in Charles River Laboratories International by 5.1% during the 1st quarter. Comerica Bank now owns 36,844 shares of the medical research company’s stock worth $3,302,000 after acquiring an additional 1,803 shares during the period. Finally, Swiss National Bank lifted its position in Charles River Laboratories International by 0.6% during the 1st quarter. Swiss National Bank now owns 78,300 shares of the medical research company’s stock worth $7,043,000 after acquiring an additional 500 shares during the period. 95.82% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Commonwealth of Pennsylvania Public School Empls Retrmt SYS Buys 33 Shares of Charles River Laboratories International, Inc. (CRL)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/17/commonwealth-of-pennsylvania-public-school-empls-retrmt-sys-buys-33-shares-of-charles-river-laboratories-international-inc-crl.html.

In other Charles River Laboratories International news, Chairman James C. Foster sold 43,154 shares of the company’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $100.00, for a total value of $4,315,400.00. Following the completion of the sale, the chairman now directly owns 361,178 shares in the company, valued at $36,117,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Ross Smith sold 2,552 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $67.10, for a total value of $171,239.20. Following the completion of the sale, the insider now owns 11,671 shares of the company’s stock, valued at $783,124.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 79,982 shares of company stock valued at $7,951,868. Insiders own 2.20% of the company’s stock.

A number of analysts have weighed in on CRL shares. Zacks Investment Research cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Robert W. Baird reaffirmed a “buy” rating and set a $114.00 price objective on shares of Charles River Laboratories International in a research report on Friday, September 1st. Citigroup Inc. reaffirmed a “neutral” rating and set a $104.00 price objective (up from $91.00) on shares of Charles River Laboratories International in a research report on Wednesday, June 28th. BidaskClub cut Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Barclays PLC reaffirmed a “hold” rating and set a $102.00 price objective on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $98.55.

Charles River Laboratories International, Inc. (NYSE CRL) opened at 106.02 on Friday. The stock has a market capitalization of $5.05 billion, a P/E ratio of 27.94 and a beta of 0.99. The stock’s 50 day moving average price is $103.01 and its 200-day moving average price is $95.28. Charles River Laboratories International, Inc. has a 52 week low of $67.20 and a 52 week high of $109.59.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.07. The business had revenue of $469.13 million during the quarter, compared to the consensus estimate of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The business’s revenue was up 8.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.20 earnings per share. Equities research analysts expect that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.